Speclipse, Inc. founded by Stanford graduates and a dermatologist, has developed a transformative, patented technology for real-time, non-invasive, in vivo cancer diagnosis based on LIPS (Laser Induced Plasma Spectroscopy) and deep learning algorithms. Clinical trials in the United States, Australia, and South Korea have shown a skin-cancer diagnostic accuracy rate of greater than 95%, higher than any other competing technologies that have attempted to achieve a similar clinical outcome. Diagnostic tools presently used by physicians such as dermascopes provides 60-70% accuracy, far below that of Spectra-Scope®. Speclipse, Inc. has acquired CE mark and TGA approval of Spectra-Scope® for both European and Australian market as well as ISO134485 certification for its manufacturing facility.